From current to future trends in pharmaceutical technology /

From Current to Future Trends in Pharmaceutical Technology explores the current trends of this field and creates a multi-aspect framework for the reader. The book covers topics on pharmaceutics, pharmaceutical engineering, pre-formulation protocols, techniques, innovative excipients, bio-printing te...

Full description

Bibliographic Details
Corporate Author:	ScienceDirect (Online service)
Other Authors:	Pippa, Natassa, Demetzos, Costas, Chountoulesi, Maria
Format:	eBook
Language:	English
Published:	London : Academic Press, 2024.
Subjects:	Pharmaceutical technology. Technology, Pharmaceutical Techniques pharmaceutiques. Electronic books.
Online Access:	Connect to the full text of this electronic book

Table of Contents:

Intro
From Current to Future Trends in Pharmaceutical Technology
Copyright
Contents
Contributors
Editors biography
Preface
Chapter 1: Fundamentals of 3D printing of pharmaceuticals
1. Introduction
2. The basic principles of 3D printing
3. Extrusion-based 3D printing
3.1. Fused deposition modeling 3D printing
3.2. Semisolid extrusion (SSE) 3D printing
3.3. Alternative extrusion-based printing techniques
4. Inkjet (IJ) 3D printing
5. VAT photopolymerization
6. Selective laser sintering
7. Selection of suitable 3D printing technique for pharmaceutical application
8. Benefits of application of 3D printing
8.1. Fabrication of dosage forms with tailored drug release by 3D printing
8.2. 3D printing of medicines for specific populations
9. Regulatory consideration
10. Conclusion and future perspective
Acknowledgments
References
Chapter 2: In silico, in situ, in vitro, and in vivo predictive methods for modeling formulation performance
1. Introduction
2. In silico design
2.1. Molecular dynamics
2.2. Molecular modeling
2.3. Discrete element modeling
2.4. Finite element method
2.5. Computational fluid dynamics
2.6. Physiologically based pharmacokinetics models
2.7. Computational tools and quality by design
3. In vitro methods
3.1. In vitro predictive dissolution models
3.1.1. Traditional in vitro models (USP I and USP II)
3.1.2. New in vitro models
3.1.2.1. Static one-compartment in vitro models
3.1.2.2. Dynamic one-compartment in vitro models
3.1.3. Dynamic two- and multicompartment in vitro models
3.2. In vitro permeability methods
3.2.1. Artificial in vitro models
3.2.2. Cell-based in vitro models
3.2.3. Tissue-based in vitro models
4. Animal models (in situ and in vivo)
4.1. Absorption rate constant.
4.2. Permeability coefficient
4.3. Oral fraction absorbed
4.4. Animal experimental models to determine intestinal permeability
4.4.1. In situ
4.4.1.1. Single-pass intestinal perfusion method
4.4.1.2. Doluisio method (closed loop)
4.4.2. In vivo
4.5. Determination of permeability in humans
4.5.1. Indirect methods
4.5.1.1. Mass balance pharmacokinetic study
4.5.1.2. Absolute bioavailability study
4.5.2. Direct methods
4.6. Correlation of permeability vs human fraction absorbed
4.7. Transit time animal models
4.7.1. Animals
4.7.1.1. Rat
4.7.1.2. Mouse
4.7.1.3. Pig
4.7.1.4. Dog
4.7.1.5. Rabbit
4.7.1.6. Nonhuman primates
4.8. Effect of excipients on permeability
5. In vitro-in vivo modeling
5.1. IVIVC in formulation development
5.1.1. Recommendations on IVIVC from regulatory agencies
5.2. Examples of PBPK IVIVC
6. New paradigms in formulation development
References
Chapter 3: Impact of co-processing on functional attributes of innovative pharmaceutical excipients
1. Introduction
2. Co-processing-process principles and CPEs manufacturing methods
2.1. Milling
2.2. Co-milling
2.3. Hot melt extrusion
2.4. Co-extrusion
2.5. Roller drying
2.6. Wet granulation
2.7. Fluid-bed granulation
2.8. Spray drying
2.9. Agglomeration
2.10. Co-crystallization
3. Morphological attributes of raw materials and co-processed products
4. Added values provided by the co-processing technology
5. The role of co-processing in designing new functional API-excipient entities
6. Summary
References
Chapter 4: Insights from molecular dynamics simulations for the design of lyophilized protein formulations
1. Advantages of freeze drying for protein pharmaceuticals
2. The freezing and drying phases may be harmful to protein stability.
3. A judicious choice of excipients can mitigate protein denaturation
4. Emerging technologies for the selection of protein formulations: Role of molecular dynamics
5. Basics of MD
6. What MD can tell us: Protein-excipient interactions and conformational transitions
7. A focus on protein-interface interactions
8. Conclusions and future perspectives
References
Chapter 5: 3D printing technologies for skin wound healing applications
1. Introduction
2. Wounds and healing processes
2.1. Definition and wound classifications
2.1.1. Causes of an injury
2.1.2. Clinical appearance
2.1.3. Nature of healing process
2.2. Wound healing processes
2.2.1. Hemostasis
2.2.2. Inflammation
2.2.3. Proliferation
2.2.4. Remodeling
3. Modern and classical wound dressing types
3.1. Traditional wound dressings
3.2. Modern dressings
3.2.1. Natural inert and bioactive polymers
3.2.2. Hydrogels
3.2.3. Tissue engineered skin substitutes (TESSs)
4. 3D printing and wound healing
4.1. History of bioprinting
4.2. Bioprinting technologies
4.2.1. Droplet-based bioprinting
4.2.2. Microextrusion-based bioprinting
4.2.3. Stereolithographic bioprinting
4.3. 3D printing toward wound healing
4.4. Drug and peptide drug delivery using 3D printed constructs
4.5. 3D printed wound dressings with antibacterial and antioxidant activity
4.6. Skin tissue engineering
5. Conclusions
References
Chapter 6: Artificial intelligence in drug discovery and clinical practice
1. Artificial intelligence
1.1. Introduction
1.2. Early intimations
1.3. Alan Turing-The birth of artificial intelligence
1.3.1. Early life and university studies
1.3.2. The ``Turing test´´
1.4. After turing
1.5. The computer revolution
1.6. What AI is considered today.
1.7. Artificial intelligence, machine learning, and deep learning
1.7.1. Artificial intelligence
1.7.2. Machine learning
1.7.3. Deep learning
1.8. Types of machine learning
1.8.1. Supervised learning
1.8.2. Unsupervised learning
1.8.3. Self-supervised learning
1.8.4. Reinforcement learning
2. Applications in drug discovery
2.1. General
2.2. Drug design
2.3. Drug repurposing
2.4. Quality by design
2.5. Formulation and excipients
2.6. 3D printing
2.7. Nanodrugs
3. Applications in clinical practice
3.1. Clinical decision support systems
3.2. Applications
3.2.1. Imaging
3.2.2. Cardiology
3.2.3. Gastroenterology
3.2.4. Ophthalmology
3.2.5. Otolaryngology
3.2.6. Anesthesiology
3.2.7. Pulmonary medicine
3.2.8. Surgery
3.2.9. COVID-19
3.2.10. Other clinical conditions
Sepsis
Psychology and psychiatry
Pharmacogenomics
3.3. Pharmacovigilance-Early adverse events detection
4. Regulatory framework
5. Challenges and future perspectives
6. Conclusions
References
Chapter 7: Drug and formulation development processes
1. Introduction
2. Drug discovery and development
2.1. Drug discovery
2.2. Preclinical development
2.2.1. Pharmacokinetics, pharmacodynamic, and toxicology studies
2.3. Clinical development
3. Formulation and process development
3.1. Preformulation properties
3.2. Biopharmaceutics properties
3.3. Route of administration
3.4. Excipient selection
3.5. Manufacturing classification system
3.6. Process development
4. Stability
5. Summary
References
Chapter 8: Current update and challenges of implementing 3D printing technologies in pharmaceutical manufacturing
1. Introduction
2. Pharmaceutical 3D printing technologies
2.1. Binder jetting
2.2. Selective laser sintering.
2.3. Fused deposition modeling (FDM)
2.4. Melt-extrusion deposition
2.5. Stereolithography
2.6. Semisolid extrusion
3. Excipients
4. Challenges of implementing 3D printing in pharmaceuticals manufacturing
5. Quality defects in 3D printed pharmaceuticals
6. Application of 3D printing in drug delivery systems
6.1. Modified release delivery systems
6.2. Amorphous solid dispersion
6.3. Transdermal delivery system
6.4. Pediatric dosage forms
6.5. Polypills
6.6. Abuse-deterrent formulations
7. Summary
References
Chapter 9: Modified-release drug delivery systems with emphasis on oral dosage forms
1. Introduction
2. Modified-release strategies
3. Advantages and disadvantages of modified-release dosage forms (Murugesan et al., 2020
Prajapat et al., 2022
Rao et a ...
3.1. Advantages of modified-release dosage forms:
3.2. Limitations of modified release dosage forms:
4. Categories of modified release systems
4.1. Diffusion-controlled systems
4.2. Dissolution-controlled systems
4.3. Diffusion and dissolution combination controlled systems
4.4. Ion exchange resin drug complexes
4.5. pH-dependent formulations
4.6. Osmotic pressure-controlled systems
5. Applications of modified-release drug delivery systems
5.1. Matrix and coated tablets
5.2. Multiple-unit solid dosage forms
5.3. Minitablets
5.4. Modified-release orodispersible formulations
5.5. Gastroretentive drug delivery systems (GRDDS)
6. Conclusions
References
Chapter 10: Additive manufacturing methods for pharmaceutical and medical applications
1. Introduction
2. Main methods of 3D printing
2.1. Fused deposition modeling
2.2. Inkjet 3D printing
2.3. VAT photopolymerization
2.4. Selective laser sintering
2.5. Semisolid extrusion (SSE).